Omnicell (NASDAQ:OMCL) Price Target Lowered to $36.00 at JPMorgan Chase & Co.

Omnicell (NASDAQ:OMCL - Free Report) had its price objective decreased by JPMorgan Chase & Co. from $44.00 to $36.00 in a report issued on Thursday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

A number of other brokerages also recently issued reports on OMCL. Benchmark reiterated a "buy" rating and issued a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Wells Fargo & Company lowered their target price on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. StockNews.com upgraded Omnicell from a "hold" rating to a "buy" rating in a research note on Thursday, March 6th. Finally, Bank of America decreased their price target on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $51.00.

Remove Ads

Omnicell Trading Up 3.5 %

OMCL traded up $1.20 during mid-day trading on Thursday, hitting $35.14. 380,919 shares of the stock were exchanged, compared to its average volume of 497,546. The firm's fifty day moving average is $39.63 and its two-hundred day moving average is $42.83. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.75. The company has a market cap of $1.64 billion, a PE ratio of 130.15, a PEG ratio of 7.53 and a beta of 0.85. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Equities analysts forecast that Omnicell will post 1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Hedge funds have recently made changes to their positions in the company. Smartleaf Asset Management LLC lifted its holdings in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares during the last quarter. Summit Investment Advisors Inc. increased its position in Omnicell by 6.9% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock worth $213,000 after buying an additional 307 shares during the period. Van ECK Associates Corp lifted its stake in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after buying an additional 315 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after acquiring an additional 355 shares during the period. Finally, Redmond Asset Management LLC grew its position in shares of Omnicell by 0.3% during the fourth quarter. Redmond Asset Management LLC now owns 121,209 shares of the company's stock worth $5,396,000 after acquiring an additional 371 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.